8-K filing — Dare Bioscience, Inc. (DARE)
Filed: 2026-09-11 AccNo: 0001401914-26-000050 Size: 153 KB Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Stocks · News reference
Daré Bioscience Announces Publication Of Results From A Phase 1 Clinical Study Evaluating Safety And Systemic Pharmacokinetics Of Topical Sildenafil Cream, 3.6%, In Healthy Adult Men In The Journal Sexual Medicine; At 71 Mg Topical Dose, Mean Maximum Plasma Concentration Of Sildenafil Was ~187-Fold Lower Than Following A 50 Mg Oral Dose
The article, titled, "An open-label, single-dose, randomized, parallel-group study of the safety and relative bioavailability of topical sildenafil cream vs oral sildenafil in healthy male adults," discusses
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Daré Bioscience Announces $908K NIH Award For Preclinical Development Of DARE-PTB2 In Preterm Birth Prevention, With Recommended Future-Year Support Of About $1.3M
Dare Bioscience Files Prospectus Related To The Resale Of Up To 8,934,345 Shares Of Common Stock By Selling Stockholders
https://www.sec.gov/Archives/edgar/data/1401914/000149315226040265/forms-1.htm